This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Dishman Carbogen Amcis Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.0 pts more than Nifty Microcap 250 and 10.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited financial results for the quarter and year ended March 31, 2025. Consolidated revenue from operations rose to ₹2,711.50 Cr from ₹2,615.77 Cr in FY24, a modest 3.7% growth. The company swung to a consolidated net profit of ₹3.24 Cr from a loss of ₹153.45 Cr last year, helped by lower exceptional items and reduced depreciation. Standalone revenue grew a stronger 22.1% to ₹399.84 Cr, though the company still reported a standalone net loss of ₹9.87 Cr (vs ₹76.41 Cr loss in FY24). Operating margin expanded sharply to 17.40% on a consolidated basis (from 11.30%) and to 17.95% standalone (from 2.08%). The statutory auditor issued an unqualified opinion but flagged an Emphasis of Matter on the change in useful life of goodwill to 99 years, which materially affects reported amortization.
A clear turnaround on the bottom line with strong margin expansion is positive for shareholders. However, the standalone business remains loss-making, and the auditor's emphasis on the extended goodwill life (which boosts reported profits) is something investors should watch closely.
| Q4 FY25 | Q4 FY24 | Change | |
|---|---|---|---|
| Revenue | ₹716.3 Cr | ₹654.7 Cr | +9.4% |
| Operating profit | ₹31.48 Cr | −₹53.27 Cr | turned positive |
| Profit after tax | ₹43.09 Cr | −₹69.92 Cr | turned positive |
| EBITDA margin | 19.7% | 9.1% | +10.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.